+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thrombolytic Drug Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Thrombolytic Drug Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Thrombolytic Drug Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 5612901
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Thrombolytic Drug Market grew from USD 1.43 billion in 2024 to USD 1.69 billion in 2025. It is expected to continue growing at a CAGR of 17.85%, reaching USD 3.84 billion by 2030.

Thrombolytic therapies have revolutionized the management of acute thrombotic events, offering life-saving interventions for conditions such as ischemic stroke, myocardial infarction, deep vein thrombosis and pulmonary embolism. As research continues to refine the balance between rapid clot dissolution and bleeding risk, a new generation of agents and delivery platforms is emerging to enhance efficacy, safety and patient outcomes. The industry’s imperative to reduce treatment delays, optimize dosing precision and expand therapeutic windows has driven innovation across molecular engineering, formulation science and point-of-care diagnostics. These advances coincide with evolving regulatory frameworks and increasing pressure to manage healthcare budgets effectively. Consequently, stakeholders-including pharmaceutical developers, medical device manufacturers, hospital systems and research institutions-must navigate a complex interplay of clinical, economic and policy dynamics. This executive summary provides an authoritative overview of the sector’s transformative shifts, the anticipated effects of upcoming trade policies, key segmentation and regional patterns, leading corporate strategies and actionable recommendations for forward-looking decision-makers.

Transformative Shifts in the Thrombolytic Landscape

The thrombolytic landscape is undergoing transformative shifts driven by breakthroughs in targeted molecular design, precision delivery systems and data-driven clinical decision support. Innovations in fibrin-specific agents, such as next-generation tissue plasminogen activators with engineered binding domains, are setting new benchmarks for rapid clot lysis with reduced hemorrhagic complications. Concurrently, catheter-based delivery coupled with microfluidic control mechanisms is enabling localized administration that maximizes drug concentration at the occlusion site while minimizing systemic exposure. Digital integration-leveraging real-time imaging and predictive analytics-facilitates personalized dosing algorithms that adapt to patient-specific risk factors and biomarker profiles. Moreover, the proliferation of portable point-of-care diagnostic platforms accelerates time to treatment, critical in stroke and myocardial infarction management where every minute of delay can translate into irreversible tissue damage. These technological advances are complemented by a growing emphasis on collaborative ecosystems, where pharmaceutical companies, device innovators and academic centers co-develop combination therapies and hybrid delivery solutions. Taken together, these developments are reshaping clinical pathways, improving patient access to timely intervention and setting the stage for the next era of thrombolytic care.

Cumulative Impact of United States Tariffs 2025

Beginning in early 2025, newly imposed United States tariffs on key imported pharmaceutical ingredients, reagent supplies and specialized manufacturing equipment are expected to reshape supply chain economics and production strategies. The additional duties on fibrinogen analogs and recombinant proteins will increase input costs for manufacturers, potentially translating into higher list prices for end users. In response, leading producers are accelerating domestic production capacity expansions and forging strategic partnerships with local contract manufacturing organizations to mitigate exposure to tariff-induced price volatility. Parallel efforts to qualify secondary global suppliers in low-tariff jurisdictions aim to diversify sourcing and ensure business continuity. At the health system level, procurement teams are recalibrating formulary decisions to balance clinical benefits against the impact of inflationary pressures. Payers and integrated delivery networks are revisiting reimbursement structures to incentivize cost-effective use of thrombolytic agents, placing greater emphasis on real-world outcomes data to support value-based contracting. Although short-term margin compression is likely, the tariffs may ultimately spur innovation in process efficiencies and supply chain resilience, accelerating the adoption of advanced manufacturing technologies such as continuous bioprocessing and single-use production platforms.

Key Segmentation Insights

The thrombolytic segment can be dissected along multiple dimensions that illuminate distinct growth drivers and adoption patterns. Based on type, the market encompasses fibrin-specific agents and non-fibrin-specific agents, with the former category-comprising desmoteplase, reteplase and tissue plasminogen activator (tPA)-further stratified into intra-arterially administered rtPA, intravenously administered rtPA and recombinant tissue plasminogen activator. On the formulation axis, injectable and powder presentations prevail, and the injectable formats split into liquid solutions, lyophilized injections and pre-filled syringes that offer varying stability and administration convenience. End users range from hospitals-differentiated into emergency services and inpatient care-to research organizations and specialty clinics that drive off-label applications. Application areas span deep vein thrombosis, ischemic stroke, pulmonary embolism and myocardial infarction, with acute myocardial infarction representing a high-urgency subset. Mechanism of action divides into clot dissolution agents-specifically plasminogen conversion catalysts-and fibrinolytic enhancement agents that modulate endogenous pathways. Route of administration contrasts intravenous delivery with emerging oral formulations designed to expand outpatient use. Patient age group categories include pediatric patients, adult patients and the geriatric population, each presenting unique dosing and safety considerations. Finally, healthcare settings range from critical care units to outpatient settings, highlighting the need for flexible administration models and point-of-care diagnostics.

Key Regional Insights

Regional patterns reveal significant variation in adoption rates, reimbursement pathways and growth trajectories. In the Americas, mature markets in North America benefit from established reimbursement frameworks that support early adoption of innovative thrombolytics, while Latin American health systems are gradually expanding access through government-sponsored programs and tiered formulary listings. Europe, Middle East & Africa present a heterogeneous landscape: Western European nations leverage centralized health technology assessment processes to drive value-based uptake, whereas certain Middle Eastern countries are enhancing critical care capacity and streamlining regulatory approvals to accelerate access. The Africa region, though nascent, shows pilot programs targeting stroke centers of excellence. In the Asia-Pacific region, dynamic growth is propelled by rising cardiovascular disease prevalence, expanding insurance coverage in China and India and ongoing investments in acute care infrastructure. Japan’s refined regulatory pathways facilitate rapid market entry for next-generation agents, and Southeast Asian markets are strengthening distribution networks to reach underserved populations.

Key Companies Insights

Competition among global and niche players is intensifying as firms seek to differentiate through proprietary formulations, device integrations and strategic collaborations. AstraZeneca PLC is leveraging its biologics expertise to explore novel tPA analogs, while Becton, Dickinson and Company focuses on advanced syringe technologies and delivery systems. Boehringer Ingelheim International GmbH has prioritized real-world evidence generation through multicenter studies, and Boston Scientific Corporation is integrating catheter-based infusion platforms with imaging guidance. Chiesi Farmaceutici S.P.A. is expanding its portfolio via licensing agreements, and Eli Lilly and Company continues to invest in molecular engineering of clot-targeting peptides. Medtronic PLC is enhancing its device pipeline with sensor-enabled infusion pumps, and Microbix Biosystems, Inc. is exploring alternative expression systems for cost-effective enzyme production. Pfizer, Inc. and Sanofi S.A. are both pursuing combination therapy strategies that pair thrombolytics with protective adjuvants. Siemens Healthineers AG is advancing its point-of-care diagnostics suite to support rapid eligibility assessments. Sigma-Aldrich Corporation remains a key reagent supplier to contract developers, and Synergy Medical Inc is positioning itself as a turnkey solutions partner for hospital systems. Taj Pharmaceuticals Ltd. is focused on emerging market expansion, and Teleflex Incorporated is optimizing drug-device co-development for seamless administration workflows.

Actionable Recommendations for Industry Leaders

To maintain a competitive edge, industry leaders should prioritize the following actions: first, accelerate investment in modular manufacturing technologies-such as continuous flow bioprocessing and single-use systems-to reduce lead times and insulate operations from tariff fluctuations. Second, deepen strategic alliances between pharmaceutical innovators and device manufacturers to co-design integrated delivery solutions and digital dosing platforms that improve clinical outcomes. Third, engage early with regulatory and reimbursement authorities to align on evidence requirements for novel thrombolytic candidates, ensuring streamlined approval and coverage pathways. Fourth, expand real-world evidence programs and health economic analyses to demonstrate value across diverse healthcare systems, supporting value-based contracting and formulary inclusion. Fifth, tailor market access strategies to regional dynamics by leveraging public-private partnerships in emerging markets and optimizing distribution networks. Sixth, pursue targeted M&A or licensing agreements to fill pipeline gaps and strengthen IP portfolios. Finally, develop patient-centric support programs-incorporating remote monitoring, adherence tools and educational initiatives-to drive improved long-term outcomes and therapy persistence.

Conclusion

The thrombolytic sector stands at an inflection point where molecular innovation, digital integration and supply chain resilience converge to define the next phase of growth. Technological advances are enhancing agent specificity and safety profiles, while point-of-care diagnostics and real-world data are reshaping clinical decision-making. Concurrently, policy shifts-such as the 2025 tariffs-are driving supply chain adaptation and stimulating investments in domestic capacity. By understanding the nuances of segmentation, regional adoption patterns and competitive positioning, stakeholders can make informed decisions that balance innovation with cost management. Proactive alignment with regulatory and reimbursement frameworks will be critical to accelerate market access for next-generation therapies. With the right mix of strategic partnerships, manufacturing agility and evidence generation, industry players are well-positioned to deliver transformative care to patients facing life-threatening thrombotic conditions.

Market Segmentation & Coverage

This research report categorizes the Thrombolytic Drug Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Fibrin-Specific Agents
    • Desmoteplase
    • Reteplase
    • Tissue Plasminogen Activator (tPA)
      • Intra-arterially Administered rtPA
      • Intravenously Administered rtPA
      • Recombinant Tissue Plasminogen Activator (rtPA)
  • Non-Fibrin-Specific Agents
    • Streptokinase
    • Tenecteplase
    • Urokinase
  • Injectable
    • Liquid Injectable
    • Lyophilized Injection
    • Pre-Filled Syringes
  • Powder
  • Hospitals
    • Emergency Services
    • Inpatient Care
  • Research Organizations
  • Specialty Clinics
  • Deep Vein Thrombosis
  • Ischemic Stroke
  • Myocardial Infarction
    • Acute Myocardial Infarction
  • Pulmonary Embolism
  • Clot Dissolution Agents
    • Plasminogen Conversion Catalysts
  • Fibrinolytic Enhancement Agents
  • Intravenous
  • Oral
  • Adult Patients
  • Geriatric Population
  • Pediatric Patients
  • Critical Care Units
  • Outpatient Settings

This research report categorizes the Thrombolytic Drug Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Thrombolytic Drug Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AstraZeneca PLC
  • Becton, Dickinson and Company (BD)
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Chiesi Farmaceutici S.P.A.
  • Eli Lilly and Company
  • Medtronic PLC
  • Microbix Biosystems, Inc.
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Sigma-Aldrich Corporation
  • Synergy Medical Inc
  • Taj Pharmaceuticals Ltd.
  • Teleflex Incorporated

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Thrombolytic Drug Market, by Type
8.1. Introduction
8.2. Fibrin-Specific Agents
8.2.1. Desmoteplase
8.2.2. Reteplase
8.2.3. Tissue Plasminogen Activator (tPA)
8.2.3.1. Intra-arterially Administered rtPA
8.2.3.2. Intravenously Administered rtPA
8.2.3.3. Recombinant Tissue Plasminogen Activator (rtPA)
8.3. Non-Fibrin-Specific Agents
8.3.1. Streptokinase
8.3.2. Tenecteplase
8.3.3. Urokinase
9. Thrombolytic Drug Market, by Formulation
9.1. Introduction
9.2. Injectable
9.2.1. Liquid Injectable
9.2.2. Lyophilized Injection
9.2.3. Pre-Filled Syringes
9.3. Powder
10. Thrombolytic Drug Market, by End User
10.1. Introduction
10.2. Hospitals
10.2.1. Emergency Services
10.2.2. Inpatient Care
10.3. Research Organizations
10.4. Specialty Clinics
11. Thrombolytic Drug Market, by Application
11.1. Introduction
11.2. Deep Vein Thrombosis
11.3. Ischemic Stroke
11.4. Myocardial Infarction
11.4.1. Acute Myocardial Infarction
11.5. Pulmonary Embolism
12. Thrombolytic Drug Market, by Mechanism of Action
12.1. Introduction
12.2. Clot Dissolution Agents
12.2.1. Plasminogen Conversion Catalysts
12.3. Fibrinolytic Enhancement Agents
13. Thrombolytic Drug Market, by Route of Administration
13.1. Introduction
13.2. Intravenous
13.3. Oral
14. Thrombolytic Drug Market, by Patient Age Group
14.1. Introduction
14.2. Adult Patients
14.3. Geriatric Population
14.4. Pediatric Patients
15. Thrombolytic Drug Market, by Healthcare Setting
15.1. Introduction
15.2. Critical Care Units
15.3. Outpatient Settings
16. Americas Thrombolytic Drug Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Thrombolytic Drug Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Thrombolytic Drug Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AstraZeneca PLC
19.3.2. Becton, Dickinson and Company (BD)
19.3.3. Boehringer Ingelheim International GmbH
19.3.4. Boston Scientific Corporation
19.3.5. Chiesi Farmaceutici S.P.A.
19.3.6. Eli Lilly and Company
19.3.7. Medtronic PLC
19.3.8. Microbix Biosystems, Inc.
19.3.9. Pfizer, Inc.
19.3.10. Sanofi S.A.
19.3.11. Siemens Healthineers AG
19.3.12. Sigma-Aldrich Corporation
19.3.13. Synergy Medical Inc
19.3.14. Taj Pharmaceuticals Ltd.
19.3.15. Teleflex Incorporated
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. THROMBOLYTIC DRUG MARKET MULTI-CURRENCY
FIGURE 2. THROMBOLYTIC DRUG MARKET MULTI-LANGUAGE
FIGURE 3. THROMBOLYTIC DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2024 VS 2030 (%)
FIGURE 22. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. THROMBOLYTIC DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. THROMBOLYTIC DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THROMBOLYTIC DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DESMOTEPLASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RETEPLASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRA-ARTERIALLY ADMINISTERED RTPA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRAVENOUSLY ADMINISTERED RTPA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (RTPA), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY STREPTOKINASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TENECTEPLASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY UROKINASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY LIQUID INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY LYOPHILIZED INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY EMERGENCY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PLASMINOGEN CONVERSION CATALYSTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY FIBRINOLYTIC ENHANCEMENT AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CRITICAL CARE UNITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY OUTPATIENT SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 60. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 91. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 103. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 105. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 106. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 107. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 108. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 109. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 113. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 114. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 115. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 118. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 121. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 122. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 124. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 128. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 180. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 182. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 183. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 184. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 185. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 186. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 188. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 190. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 191. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 192. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 194. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 195. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 196. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 197. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 198. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 199. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 200. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 201. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 203. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 205. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 206. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 207. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 213. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 225. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 226. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 227. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 228. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 229. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 231. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 235. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 236. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 237. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 240. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 241. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 242. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 243. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 267. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 272. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 280. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 281. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 282. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 284. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 285. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 286. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 287. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 288. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 289. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 290. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 291. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 295. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 296. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 297. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 299. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 300. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 301. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 302. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 303. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 304. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 305. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 306. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 308. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 310. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 311. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 312. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 314. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 315. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 316. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 317. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 318. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 319. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 320. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 321. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 323. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2030 (USD MILLION)
TABLE 325. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 326. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY CLOT DISSOLUTION AGENTS, 2018-2030 (USD MILLION)
TABLE 327. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 329. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 330. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 331. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 332. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR (TPA), 2018-2030 (USD MILLION)
TABLE 333. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY NON-FIBRIN-SPECIFIC AGENTS, 2018-2030 (USD MILLION)
TABLE 334. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 335. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 336. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 337. VIETN

Companies Mentioned

  • AstraZeneca PLC
  • Becton, Dickinson and Company (BD)
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Chiesi Farmaceutici S.P.A.
  • Eli Lilly and Company
  • Medtronic PLC
  • Microbix Biosystems, Inc.
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Sigma-Aldrich Corporation
  • Synergy Medical Inc
  • Taj Pharmaceuticals Ltd.
  • Teleflex Incorporated

Methodology

Loading
LOADING...

Related Topics

Related Reports

Catheter-Directed Thrombolysis Devices Market by Product Type, Material Type, Device Design, Application, Therapeutic Class, Patient Age Group, End User - Global Forecast 2025-2030 - Product Image

Catheter-Directed Thrombolysis Devices Market by Product Type, Material Type, Device Design, Application, Therapeutic Class, Patient Age Group, End User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Thrombosis Drugs - Global Strategic Business Report - Product Image

Thrombosis Drugs - Global Strategic Business Report

  • Report
  • 387 Pages
  • Global
From
Reteplase Market by Patient Type (Adult, Geriatric, Pediatric), Therapeutic Area (Acute Myocardial Infarction, Pulmonary Embolism), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Reteplase Market by Patient Type (Adult, Geriatric, Pediatric), Therapeutic Area (Acute Myocardial Infarction, Pulmonary Embolism), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Acute Ischemic Stroke Therapeutics Market 2024-2028 - Product Image

Acute Ischemic Stroke Therapeutics Market 2024-2028

  • Report
  • 184 Pages
  • Global
From
Myocardial Infarction (MI) Therapeutics Market 2024-2028 - Product Image

Myocardial Infarction (MI) Therapeutics Market 2024-2028

  • Report
  • 149 Pages
  • Global
From

About the Thrombolytics Market

Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen. The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.